Prescription Drug News and Research

RSS

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

FDA's Oncologic Drugs Advisory Committee votes in favor of FOLOTYN NDA

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

3 Sep 2009

Drug stores consider how reform efforts may affect drug stores

If reform passes, CVS expects profits to remain steady while benefit managers worry about other drug stores' plans to go around them and negotiate directly on price.

1 Sep 2009

Walgreens to provide flue shots faster and easier this season

Walgreens (NYSE:WAG)(NASDAQ:WAG) is making it faster and easier to get a flu shot this season. The nation’s largest drugstore chain today announced it will begin offering seasonal flu shots on Sept. 1 at more than 7,000 points of care nationwide, including nearly all of its stores in 50 states and almost 350 in-store Take Care Clinics.

31 Aug 2009

Mark Farrah Associates partners with Strenuus to launch Medicare Benefits Analyzer

Mark Farrah Associates (MFA) announces the addition of Medicare Benefits Analyzer to its online product portfolio. “We are very pleased to be partnering with Strenuus to launch this new product.

31 Aug 2009

First Edition: August 31, 2009

Today's headlines hint that summer's almost over, but the heat will still be on for health reform.

31 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation (ABNR) involves a safe, medically-assisted withdrawal from Benzodiazepines in a hospital setting. This advanced approach to Benzodiazepine withdrawal offers patients another alternative to traditional benzodiazepine detoxification, which even when done gradually, can be extremely dangerous and even life threatening.

29 Aug 2009

Ipsen Group announces first-half 2009 financial results

The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group’s results for the first half 2009, published today. The full 2009 half year financial report is available on the Group’s web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.

28 Aug 2009

Senior citizens are paying escalating cost for their health care says HHS Secretary Kathleen Sebelius

HHS Secretary Kathleen Sebelius today issued a new report, America’s Seniors and Health Insurance Reform: Protecting Coverage and Strengthening Medicare. The report highlights the problems with the status quo that leave seniors paying escalating costs for their health care while outlining how health insurance reform will strengthen Medicare and protect coverage for seniors.

28 Aug 2009

Prescription Solutions launches consumer website that features updated content and drug pricing tool

Prescription Solutions, a leading pharmacy benefits management organization and a UnitedHealth Group (NYSE: UNH) company, today announced the launch of its refreshed consumer website, www.PrescriptionSolutions.com, featuring enhanced functionality, updated content, and simplified navigation. The site makes prescription drug information more accessible and provides education customers need to make informed health care choices.

27 Aug 2009

Walgreens collaborates with Caterpillar to provide transparent prescription drug pricing for employers

Walgreens today announced an agreement with Caterpillar Inc. (NYSE: CAT) that establishes a direct relationship for the purchase of prescription drugs using a transparent pricing model.

27 Aug 2009

Sen. Edward M. Kennedy -- health care champion -- dies

Sen. Edward M. Kennedy had a hand in nearly every piece of health care legislation that moved through Congress during his eight-term Senate tenure. He died Tuesday night of brain cancer at age 77.

27 Aug 2009

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

FDA accepts Labopharm's response for its novel trazodone formulation

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.

26 Aug 2009

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.

26 Aug 2009

Customized health plan introduced by American Community

As Nebraska employers seek out additional ways to reduce rising healthcare costs, American Community Mutual Insurance Company announced today the addition of Latitude(TM), a small group product that allows employers to customize a health plan with the benefits that employees want at a price that business owners can afford.

26 Aug 2009

Medicare's Part D program subsidizes cost of prescription drugs for Medicare beneficiaries

Medicare's Part D program, designed to subsidize the cost of prescription drugs for Medicare beneficiaries, has been the subject of much debate. Proponents have touted the plan's ability to expand access to prescription drugs to seniors; critics have long questioned its design and user-friendly appeal.

26 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

New RAND study finds that Prescription Benefit Program for Medicare recipients surpasses expectations

The program created to provide Medicare recipients with prescription drug benefits exceeded expectations during its first two years, extending pharmacy coverage to most seniors while reducing their overall spending on drugs, according to a new RAND Corporation study.

25 Aug 2009

Prescription Drug News and Research

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

FDA's Oncologic Drugs Advisory Committee votes in favor of FOLOTYN NDA

Drug stores consider how reform efforts may affect drug stores

Walgreens to provide flue shots faster and easier this season

Mark Farrah Associates partners with Strenuus to launch Medicare Benefits Analyzer

First Edition: August 31, 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

Ipsen Group announces first-half 2009 financial results

Senior citizens are paying escalating cost for their health care says HHS Secretary Kathleen Sebelius

Prescription Solutions launches consumer website that features updated content and drug pricing tool

Walgreens collaborates with Caterpillar to provide transparent prescription drug pricing for employers

Sen. Edward M. Kennedy -- health care champion -- dies

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

FDA accepts Labopharm's response for its novel trazodone formulation

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Customized health plan introduced by American Community

Medicare's Part D program subsidizes cost of prescription drugs for Medicare beneficiaries

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

New RAND study finds that Prescription Benefit Program for Medicare recipients surpasses expectations

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News